Thinly traded nano cap Therapix Biosciences (TRPX +20.1%) is up on a 14x surge in volume in reaction to positive results from a single-arm open-label study evaluating lead candidate THX-110 in adults with obstructive sleep apnea (OSA).
10 patients were enrolled and nine completed the trial (one dropped out due to treatment-related dizziness). 56% (n=5/9) showed significant improvement in their condition as measured by a scale called AHI with an average value reduction of ~54%.
Two participants experienced mild side effects that resolved when THC (psychoactive component of cannabis) dosages were reduced to 5 mg/day.
THX-110, a combination of the dronabinol (synthetic THC) and palmitoylethanolamide, a cannabinoid mimetic, is also being developed to treat Tourette syndrome and pain.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.